Basel Medical Group Ltd (NASDAQ: BMGL): Corporate Profile & Financials
Source: Basel Medical Group Ltd Form 20-F 2026
Basel Medical Group Ltd is a BVI business company incorporated under the laws of the British Virgin Islands, functioning as the ultimate holding company for an integrated medical services group headquartered and operating in Singapore. Operating through its operating subsidiary networks, the Group manages a ecosystem of specialist orthopedic clinics, general practice facilities, trauma centers, neurosurgical care centers, and physiotherapy units.
- Specialist Clinics – Corporate Inpatients: Segment revenue: $1.15 M (8.99%).
- Specialist Clinics – Corporate Outpatients: Segment revenue: $1.84 M (14.40%).
- Specialist Clinics – Individual Inpatients: Segment revenue: $2.42 M (18.92%).
- Specialist Clinics – Individual Outpatients: Segment revenue: $3.61 M (28.17%).
- General Practice Clinics – Corporate Patients: Segment revenue: $2.32 M (18.10%).
- General Practice Clinics – Individual Patients: Segment revenue: $1.46 M (11.42%).
📋 Quick Facts / Company Snapshot: Basel Medical Group Ltd
| Attribute | Value |
|---|---|
| Official Company Name | Basel Medical Group Ltd |
| Ticker Symbol | BMGL |
| Primary Exchange | The Nasdaq Stock Market LLC (Nasdaq Capital Market) |
| Principal Executive Offices | 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore 258499 |
| Industry / Sector | Healthcare / Medical Clinics & Specialist Healthcare Services |
| Jurisdiction of Incorporation | British Virgin Islands |
| Date of Incorporation | August 10, 2023 |
| First Clinic Operating History | 2001 (First orthopedic clinic set up in Singapore) |
| Total Employees | 74 full-time employees (as of June 30, 2026) |
| Medical Practitioners Count | 13 medical practitioners (4 specialists, 9 general practitioners) |
| Primary Operating Market | Singapore |
| Major Operating Subsidiaries | Basel Medical Group Pte. Ltd., Singapore Sports & Orthopaedic Clinic Pte. Ltd., Bethesda Medical Pte. Ltd. |
| Parent / Controlling Shareholder | Rainforest Capital VCC (Sub-funds: Basel Medical Fund, Fan Mingchun, Wei Hua, Baselcorp Capital) |
| Chief Executive Officer | Dr. Darren Yen Feng Chhoa |
| Interim Chief Financial Officer | Alton Chun How Neo |
| Chief Commercial Officer | Tan Boon Chye (Darren) |
| Chairman of the Board | Xinwen Yang |
| External Auditor | NLA DFK Assurance PAC (Singapore) |
| Company Contact Person | Dr. Darren Yen Feng Chhoa (contact@baselmedical.com) |
| External Website | https://baselmedical.com/ |
1. Corporate Identity: Basel Medical Group Ltd Overview & History
The Big Picture
Basel Medical Group Ltd is a BVI business company incorporated under the laws of the British Virgin Islands, functioning as the ultimate holding company for an integrated medical services group headquartered and operating in Singapore. Operating through its operating subsidiary networks, the Group manages a ecosystem of specialist orthopedic clinics, general practice facilities, trauma centers, neurosurgical care centers, and physiotherapy units.
The Group’s primary specialist operations are strategically anchored at Gleneagles Medical Centre in Singapore, offering medical diagnosis, consultation, minor surgical services, and conservative orthopedic treatments. Major surgical operations are conducted at premier private healthcare facilities across Singapore, including Gleneagles Hospital, Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Parkway East Hospital, Mount Alvernia Hospital, and Farrer Park Hospital.
The company maintains preferred provider network status with over 20 private health insurance providers and serves more than 300 corporate accounts across Singapore. Additionally, the Group’s medical professionals are MediSave accredited, enabling Singapore citizens and permanent residents to utilize national medical savings schemes and Integrated Shield Plans for eligible treatments.
The Founders & Their Legacy
The foundation of the Group’s medical practice traces back to 2001, when founder Dr. Kevin Yip established the group’s inaugural orthopedic clinic in Singapore. Dr. Yip, an orthopedic surgeon holding degrees from the University of London, Royal College of Surgeons of Edinburgh, Hong Kong College of Orthopaedic Surgeons, and the Academy of Medicine, Singapore, established the clinical framework that guided the practice’s initial expansion.
Under Dr. Yip’s guidance, the operating practice grew into Singmed Specialists, establishing prominent specialty clinics including Spine & Orthopaedics Centre (Singapore) and Singapore Sports & Orthopaedics Clinic. In 2020, Dr. Yip reorganized the individual operating entities under a centralized corporate holding structure, setting the stage for institutional investment and subsequent capital market expansion.
Key institutional evolution milestones in the Group’s ownership history include:
| 2001–2004 | Establishment of the first orthopedic clinic and incorporation of Singapore Sports & Orthopaedic Clinic Pte. Ltd. (SSO Clinic) in 2004. |
|---|---|
| October 2020 | Internal reorganization transferring operational clinic shares from Dr. Kevin Yip to Singmed Specialists Pte. Ltd. |
| June 2023 | Full acquisition of Singmed Specialists by asset management firm AIP Investment Partners Pte. Ltd. via its sub-fund Basel Medical Fund under Rainforest Capital VCC, leading to the corporate renaming to Basel Medical Group. |
| August 2023 | Incorporation of Basel Medical Group Ltd in the British Virgin Islands as the top-tier holding company. |
| February 2025 | Successful initial public offering and listing on the Nasdaq Capital Market under the ticker symbol BMGL. |
| April 2025 | Strategic acquisition of Bethesda Medical Pte. Ltd., adding six general practice clinics across Singapore. |
The Journey: History & Evolution
Following its institutional acquisition in mid-2023, Basel Medical Group embarked on an aggressive corporate transformation aimed at expanding beyond its core orthopedic specialty into a multi-specialty regional medical provider. The reorganization in August 2023 consolidated 100% of the shares of Basel Medical Group Pte. Ltd. under the BVI parent entity, creating the public vehicle that subsequently listed on Nasdaq in February 2025.
A transformative expansion occurred on April 30, 2025, when the Group completed the acquisition of 100% of Bethesda Medical Pte. Ltd. from Silkroute Biomed Healthcare Pte. Ltd. for a total consideration of S$10,339,950 (US$8.00 million in tranches). This transaction dramatically broadened the Group’s operational footprint, integrating six general practice clinics located in high-density corporate and residential hubs across Singapore, including Suntec City Mall, Grantral Mall, Toa Payoh, Margaret Drive, Tampines, and Beach Road.
In mid-2026, the company executed corporate governance and capital restructuring measures to optimize its equity base and maintain Nasdaq compliance. On June 22, 2026, the company effected a 1-for-12 reverse share split of its ordinary shares, successfully regaining full compliance with Nasdaq’s minimum bid price requirement in July 2026. Shortly thereafter, in October 2026, the company completed a registered direct offering raising gross proceeds of US$7.98 million (net proceeds of US$7.28 million) to support ongoing working capital requirements and enterprise growth.
The Corporate Umbrella
The parent entity, Basel Medical Group Ltd (BVI), exerts full ownership and corporate control over an intermediate holding entity in Singapore, which in turn holds direct or majority equity ownership in fourteen dedicated operating subsidiaries. Each subsidiary is organized to manage specific clinical practices, administrative services, day surgery units, or specialized healthcare capabilities.
The primary operating subsidiaries within the Group structure include:
- Basel Medical Group Pte. Ltd. (Singapore): Intermediate holding company (100% owned; formerly Singmed Specialists Pte. Ltd.).
- Singapore Sports & Orthopaedic Clinic Pte. Ltd. (Singapore): Specialist medical and clinical services (100% owned).
- Singapore Sports & Orthopaedic Services Pte. Ltd. (Singapore): Specialized day surgical and clinic services (100% owned).
- Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd. (Singapore): Specialist orthopedic clinical services (100% owned).
- Singapore Knee, Sports and Orthopaedic Services Pte. Ltd. (Singapore): Specialized clinical and surgical services (100% owned).
- SSOC Pte. Ltd. & SSOS Pte. Ltd. (Singapore): Specialist clinical operations (100% owned).
- Bethesda Medical Pte. Ltd. & Oasis Medical Clinic Pte. Ltd. (Singapore): General practice clinic chain and healthcare services (100% owned).
- Pharma Avenue Pte. Ltd. (Singapore): Health and ancillary services (100% owned; formerly Singapore Sports and Physiotherapy Centre Pte. Ltd.).
- SSOC Novena Pte. Ltd., SSOC Farrer Park Pte. Ltd., SSOC Orchard Pte. Ltd. (Singapore): Regional specialist clinic practices (53% owned).
2. The Business Engine: Basel Medical Group Ltd Business Model & Revenue Segments
The Core Divisions
Basel Medical Group classifies its operating revenue streams into two primary operating divisions: Specialist Clinics (incorporating Orthopedics, Trauma, Sports Medicine, Neurosurgery, and Physiotherapy) and General Practice Clinics (derived from the Bethesda Medical acquisition). Within these divisions, patient encounters are further broken down into Corporate Patients (referred by employer contracts or insurer panels) and Individual Patients (direct walk-ins and private elective patients).
The following table provides the comprehensive breakdown of group revenue by clinic type, patient category, and inpatient/outpatient treatment classification for the financial years ended June 30, 2025, and June 30, 2026:
| Division & Patient Category (in S$ / US$) | FY2026 (US$) | FY2026 (S$) | FY2026 (%) | FY2025 (S$) | FY2025 (%) | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Specialist Clinics – Corporate Inpatients | 1,152,000 | 1,479,000 | 9.0 | 1,448,000 | 13.0 | -20.44% |
| Specialist Clinics – Corporate Outpatients | 1,844,000 | 2,367,000 | 14.0 | 2,388,000 | 21.0 | -22.78% |
| Total Specialist Corporate Revenue | 2,996,000 | 3,846,000 | 23.0 | 3,836,000 | 34.0 | -21.90% |
| Specialist Clinics – Individual Inpatients | 2,424,000 | 3,112,000 | 19.0 | 2,093,000 | 18.0 | +15.81% |
| Specialist Clinics – Individual Outpatients | 3,608,000 | 4,631,000 | 28.0 | 4,554,000 | 40.0 | -20.77% |
| Total Specialist Individual Revenue | 6,032,000 | 7,743,000 | 47.0 | 6,647,000 | 58.0 | -9.25% |
| General Practice Clinics – Corporate Patients | 2,318,000 | 2,975,000 | 19.0 | 635,000 | 6.0 | +265.04% |
| General Practice Clinics – Individual Patients | 1,463,000 | 1,878,000 | 11.0 | 202,000 | 2.0 | +624.26% |
| Total Group Consolidated Revenue | 12,809,000 | 16,442,000 | 100.0 | 11,320,000 | 100.0 | +13.15% |
The Global Product Catalog
Basel Medical Group delivers an integrated spectrum of outpatient and inpatient clinical services, emphasizing advanced diagnostic, surgical, and therapeutic treatments across sub-specialty disciplines.
Primary medical specialties and services include:
- Surgical Orthopedics & Trauma Care: Advanced surgical intervention utilizing keyhole and minimally invasive techniques, robotic-assisted joint replacement (knee and hip), bone fracture fixation, arthroscopy, and complex foot and ankle surgery.
- Non-Surgical Orthopedics: Outpatient conservative management, therapeutic joint injections, splinting, casting, specialist consultations, and second opinion evaluations.
- Neurosurgery & Spine Care: Management and surgical intervention for disorders of the brain and spine, including degenerative disc disease, back and neck pain, spinal scoliosis, nerve entrapment, brain tumors, aneurysms, concussions, and epilepsy.
- Physiotherapy & Rehabilitation: Evidence-based physical therapy, post-operative rehabilitation, functional movement restoration, sports injury conditioning, and custom physical therapy plans.
- General Practice & Health Screening: Primary care consultations, chronic disease management, corporate health screening, diagnostic laboratory testing, mental health support, and women’s health consultations.
The Names You Know
The Group operates its specialist and primary care networks under two well-established clinical brand names in Singapore: Singmed Specialists / Singapore Sports & Orthopaedic Clinic (SSOC) and Bethesda Medical. The Group’s branding strategy emphasizes specialized clinical excellence combined with accessible, multi-location primary healthcare.
To safeguard its commercial identity, the Group holds registered trademark protection in Singapore for its core brand logo and maintains proprietary control over digital web domains, including www.orthopaedicclinic.com.sg, www.baselorthopaedics.com, www.baselneurosurgery.com, and www.baselmedical.com.
Mapping the Global Reach
The Group’s physical clinical footprint and revenue-generating operations are concentrated entirely within the Republic of Singapore. For the fiscal years ended June 30, 2025, and June 30, 2026, 100% of reported revenue was derived from patient care and corporate medical contracts executed in Singapore.
While operating locally in Singapore, the Group treats an international patient base comprising Singapore residents, foreign expatriates, regional medical travelers, and corporate employees from regional construction, marine, and oil and gas enterprises operating in Southeast Asia.
The Brick & Mortar Footprint
The Group maintains a real estate footprint of leased medical facilities located in private hospital specialist centers, commercial shopping centers, and urban hubs across Singapore.
The active clinic locations operated by the Group include:
- Gleneagles Medical Centre (Specialist & HQ): 6 Napier Road, #02-10/11 & #03-07, Gleneagles Medical Centre, Singapore 258499.
- Mount Elizabeth Novena Specialist Centre: 38 Irrawaddy Road, #08-63, Mount Elizabeth Novena Specialist Centre, Singapore.
- Bethesda Medical Clinic (Suntec City): 3 Temasek Boulevard, #03-330, Suntec City Mall, Singapore.
- Bethesda Medical Clinic (Grantral Mall): 601 Macpherson Road, #01-04, Grantral Mall, Singapore.
- Bethesda Medical Clinic (Toa Payoh): 500 Lorong 6 Toa Payoh, #04-33, Toa Payoh Hub, Singapore.
- Bethesda Medical Clinic (Margaret Drive): 38 Margaret Drive, #02-03, Singapore.
- Bethesda Medical Clinic (Tampines): 406 Tampines Street 41, #01-31, Singapore.
- Bethesda Medical Clinic (Beach Road): 152 Beach Road, #03-08 & #03-08A, Gateway East, Singapore.
3. The Financial Health: Basel Medical Group Ltd (FY 2026) Audited Financial Statements
Earnings, Expenses & Profits: Basel Medical Group Ltd Income Statement
For the fiscal year ended June 30, 2026, Basel Medical Group achieved consolidated revenue of S$16,441,770 (US$12,808,828), representing an increase of 45.2% compared to S$11,319,944 in FY2025. This top-line expansion was driven by the full-year inclusion of Bethesda Medical’s general practice chain and heightened overall demand for specialist orthopedic treatments.
Operating financial performance registered a improvement as consolidated loss before tax contracted sharply from S$11,053,571 in FY2025 to S$1,249,833 (US$973,673) in FY2026. The prior period’s loss was heavily distorted by a non-cash goodwill impairment charge of S$10,349,252 recognized upon the acquisition of Bethesda Medical. On an after-tax basis, net loss for FY2026 stood at S$1,429,395 (US$1,113,559), compared to a net loss of S$10,636,178 in FY2025.
The following table presents the complete audited Consolidated Statement of Profit or Loss and Comprehensive Income for the fiscal years ended June 30, 2025, and June 30, 2026:
| Consolidated Line Item (in S$ / US$) | FY2026 (US$) | FY2026 (S$) | FY2025 (S$) | Latest YoY (%) |
|---|---|---|---|---|
| Revenue | 12,808,828 | 16,441,770 | 11,319,944 | +13.15% |
| Other income | 3,950,333 | 5,070,759 | 1,752,489 | +125.41% |
| Consumables, medical supplies and other related expenses | -3,066,510 | -3,936,258 | -2,552,460 | +20.14% |
| Employee benefit expenses | -7,195,482 | -9,236,322 | -6,397,933 | +12.47% |
| Depreciation expense | -3,034,672 | -3,895,390 | -1,181,128 | +156.93% |
| Rent expense | -5,191 | -6,663 | -141,075 | -96.32% |
| Other operating expense | -4,073,142 | -5,228,400 | -3,300,208 | +23.42% |
| Impairment loss on goodwill | 0 | 0 | -10,349,252 | -100.00% |
| Finance cost | -357,837 | -459,329 | -203,948 | +75.46% |
| Loss before tax | -973,673 | -1,249,833 | -11,053,571 | -91.19% |
| Income tax (expense) / benefit | -139,886 | -179,562 | 417,393 | N/M |
| Loss for the year (Total comprehensive loss) | -1,113,559 | -1,429,395 | -10,636,178 | -89.53% |
| Loss attributable to: Owners of the Company | -582,720 | -747,995 | -10,635,677 | -94.52% |
| Loss attributable to: Non-controlling interests | -530,839 | -681,400 | -501 | +105855.89% |
| Basic and diluted loss per share | -0.61 | -0.78 | -0.57 | +7.02% |
| Weighted average ordinary shares (Basic and Diluted) | 1,582,111 | 1,582,111 | 18,785,750 | -91.58% |
Assets, Debts & Equity: Basel Medical Group Ltd Balance Sheet
As of June 30, 2026, Basel Medical Group held total assets of S$17,788,122 (US$13,745,553), supported by current assets of S$12,129,469 and non-current assets of S$5,658,653. The asset composition is led by trade and other receivables of S$10,341,500—which includes S$7,060,553 in deposits, of which S$4,701,220 represents payments for custodian services earmarked for future corporate expansion—and right-of-use lease assets of S$5,313,472.
Total liabilities stood at S$13,251,795 (US$10,240,163) at fiscal year-end 2026, comprising S$9,861,868 in current obligations and S$3,389,927 in non-current liabilities. Total financial debt includes S$6,081,509 in lease liabilities for clinical real estate and S$2,575,135 in bank borrowings (Term Loan #13). Total equity stood at S$4,536,327 (US$3,505,390), with equity attributable to owners of the parent reaching S$5,056,545.
The following table provides the audited Consolidated Balance Sheets as of June 30, 2025, and June 30, 2026:
| Balance Sheet Line Item (in S$ / US$) | FY2026 (US$) | FY2026 (S$) | FY2025 (S$) | Latest YoY (%) |
|---|---|---|---|---|
| Right-of-use assets | 4,105,921 | 5,313,472 | 4,949,372 | -17.04% |
| Property and equipment | 221,172 | 286,219 | 388,657 | -43.09% |
| Deferred tax assets | 45,562 | 58,962 | 47,875 | -4.83% |
| Total Non-Current Assets | 4,372,655 | 5,658,653 | 5,385,904 | -18.81% |
| Inventories | 178,438 | 230,917 | 489,062 | -63.51% |
| Trade and other receivables | 7,991,266 | 10,341,500 | 9,489,266 | -15.79% |
| Cash and cash equivalents | 409,464 | 529,887 | 3,044,466 | -86.55% |
| Amount due from related parties | 768,730 | 994,812 | 0 | N/M |
| Deferred offering costs | 25,000 | 32,353 | 31,797 | -21.38% |
| Current tax assets | 0 | 0 | 239,407 | -100.00% |
| Total Current Assets | 9,372,898 | 12,129,469 | 13,293,998 | -29.50% |
| Total Assets | 13,745,553 | 17,788,122 | 18,679,902 | -26.42% |
| Deferred tax liabilities | 0 | 0 | 123,810 | -100.00% |
| Borrowings (Non-current) | 2,619,525 | 3,389,927 | 2,956,727 | -11.40% |
| Total Non-Current Liabilities | 2,619,525 | 3,389,927 | 3,080,537 | -14.97% |
| Trade and other payables | 2,746,493 | 3,554,236 | 6,574,785 | -58.23% |
| Borrowings (Current) | 4,069,791 | 5,266,717 | 2,121,119 | +91.87% |
| Amount due to related parties | 744,038 | 962,860 | 1,450,305 | -48.70% |
| Asset retirement obligation | 59,501 | 77,000 | 15,000 | +296.67% |
| Provision for income tax | 815 | 1,055 | 0 | N/M |
| Total Current Liabilities | 7,620,638 | 9,861,868 | 10,161,209 | -25.00% |
| Total Liabilities | 10,240,163 | 13,251,795 | 13,241,746 | -22.67% |
| Share capital | 25,609,109 | 34,208,562 | 34,208,562 | -25.14% |
| Merger reserve arising from group restructuring | -18,362,500 | -24,455,170 | -24,455,170 | -24.91% |
| Retained earnings | -3,248,454 | -4,323,727 | -3,854,948 | -15.73% |
| Translation reserve | -90,773 | -373,120 | -463,787 | -80.43% |
| Non-controlling interest | -401,992 | -520,218 | 3,499 | N/M |
| Total Equity | 3,505,390 | 4,536,327 | 5,438,156 | -35.54% |
Cash Flow & Capital Allocation: Basel Medical Group Ltd Cash Flow Statement
During the fiscal year ended June 30, 2026, Basel Medical Group generated operating cash flows before working capital changes of S$3,808,148 (US$2,904,682), reflecting underlying operational cash generation before working capital movements. Working capital outflows were led by an increase in trade and other receivables of S$1,190,986 and a reduction in trade and other payables of S$3,020,549, resulting in net cash used in operating activities of S$635,207 (US$531,956).
Investing cash outflows totaled S$104,241 (US$80,506) for FY2026, primarily driven by capital expenditures of S$248,233 for clinic medical equipment and leasehold additions. Net financing cash outflows reached S$1,775,131 (US$1,371,710), reflecting lease principal repayments of S$2,868,009 and debt repayments of S$424,865, offset by S$3,000,000 in new bank loan proceeds (Term Loan #13).
The following table outlines the audited Consolidated Statement of Cash Flows for FY2025 and FY2026:
| Consolidated Cash Flow Line Item (in S$ / US$) | FY2026 (US$) | FY2026 (S$) | FY2025 (S$) | Latest YoY (%) |
|---|---|---|---|---|
| Loss before tax | -973,673 | -1,249,833 | -11,053,571 | -91.19% |
| Bad debts written off | 0 | 0 | 602,264 | -100.00% |
| Share-based payment expense | 233,713 | 300,000 | 0 | N/M |
| Unrealised forex gain or loss | 17,761 | 90,112 | 0 | N/M |
| Provision for estimated credit losses | 206,407 | 277,380 | 277,101 | -25.51% |
| Provision of asset retirement obligation cost | 48,301 | 62,000 | 0 | N/M |
| Depreciation of property and equipment | 273,187 | 350,671 | 107,659 | +153.75% |
| Amortisation of right-of-use assets | 2,761,485 | 3,544,719 | 1,073,469 | +157.25% |
| Fixed asset written off | 0 | 0 | 206,287 | -100.00% |
| Write off of right-of-use assets / lease liabilities | -12,089 | -15,645 | 0 | N/M |
| Impairment loss on goodwill | 0 | 0 | 10,349,252 | -100.00% |
| Interest income | -5,526 | -7,093 | 0 | N/M |
| Interest expense | 355,116 | 455,837 | 203,948 | +74.12% |
| Operating cash flows before working capital changes | 2,904,682 | 3,808,148 | 1,766,409 | +64.44% |
| Changes in inventories | 199,478 | 258,145 | -304,262 | N/M |
| Changes in trade and other receivables | -920,320 | -1,190,986 | -8,687,432 | -89.41% |
| Changes in trade and other payables | -2,334,092 | -3,020,549 | 4,033,506 | N/M |
| Income tax paid | -57,647 | -73,997 | -648,293 | -91.11% |
| Interest paid | -324,057 | -415,968 | -203,948 | +58.89% |
| Net cash used in operating activities | -531,956 | -635,207 | -4,044,020 | -86.85% |
| Acquisition of property and equipment (Capital Expenditures) | -191,819 | -248,233 | -556,940 | -65.56% |
| Profit attributable to non-controlling interest | 105,787 | 136,899 | 0 | N/M |
| Acquisition of subsidiary (net cash outflow) | 0 | 0 | -10,339,950 | -100.00% |
| Interest received | 5,526 | 7,093 | 0 | N/M |
| Net cash used in investing activities | -80,506 | -104,241 | -10,896,890 | -99.26% |
| Deferred offering costs paid | 0 | 0 | 1,556,226 | -100.00% |
| Net change in amount due to related parties | -376,666 | -487,445 | 138,915 | N/M |
| Net change in amount due from related parties | -768,729 | -994,812 | 10,557,240 | N/M |
| Proceeds from borrowings | 2,318,213 | 3,000,000 | 4,000,000 | -42.04% |
| Payment of principal portion of lease liabilities | -2,216,219 | -2,868,009 | -1,321,600 | +67.69% |
| Write off of right-of-use assets | 0 | 0 | 183,195 | -100.00% |
| Repayment of borrowings | -328,309 | -424,865 | -8,261,290 | -96.03% |
| Decrease in amount due to former director | 0 | 0 | -111,459 | -100.00% |
| Non-controlling interest contributions | 0 | 0 | 3,499 | -100.00% |
| Share issuance proceeds (net) | 0 | 0 | 9,753,384 | -100.00% |
| Net cash (used in) / generated from financing activities | -1,371,710 | -1,775,131 | 16,498,110 | N/M |
| Net (decrease) / increase in cash and cash equivalents | -1,984,172 | -2,514,579 | 1,557,200 | N/M |
| Cash and cash equivalents at beginning of year | 2,393,636 | 3,044,466 | 1,951,053 | +22.68% |
| Effects of currency translation on cash | 0 | 0 | -463,787 | -100.00% |
| Cash and cash equivalents at end of year | 409,464 | 529,887 | 3,044,466 | -86.55% |
Funding the Future: R&D and Expansion Spending
Capital investments across the Group center on adding diagnostic equipment, surgical robotics, and modernizing clinic leasehold infrastructure across its Singapore practices. In FY2026, direct property and equipment purchases totaled S$248,233 (US$191,819), following S$556,940 deployed in FY2025.
In addition to physical equipment purchases, the Group maintains substantial deposit balances earmarked for corporate development, including S$4,701,220 held in custodian accounts designated for future healthcare mergers and acquisitions in Singapore. The Group also upgraded its IT infrastructure, medical records security systems, and digital booking software to expand direct online appointments and patient intake.
4. The Corporate Family Tree: Basel Medical Group Ltd Subsidiaries & Acquisitions
Subsidiaries, Associates, & Shared Ventures
Basel Medical Group Ltd maintains direct and indirect equity interests across fourteen corporate entities operating in Singapore. All active operations are conducted through these dedicated subsidiaries.
The Group’s corporate ownership structure comprises:
- 100% Wholly-Owned Operating Entities: Basel Medical Group Pte. Ltd., Singapore Sports & Orthopaedic Clinic Pte. Ltd., Singapore Sports & Orthopaedic Services Pte. Ltd., Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd., Singapore Knee, Sports and Orthopaedic Services Pte. Ltd., SSOC Pte. Ltd., SSOS Pte. Ltd., Pharma Avenue Pte. Ltd., Bethesda Medical Pte. Ltd., Oasis Medical Clinic Pte. Ltd.
- 53% Majority-Owned Entities: SSOC Novena Pte. Ltd., SSOC Farrer Park Pte. Ltd., SSOC Orchard Pte. Ltd.
- 65% Majority-Owned Entity: Eyetrust Medical Pte. Ltd. (officially struck off by ACRA on September 17, 2026).
Strategic Investments & Minority Stakes
The Group holds no material non-consolidated minority equity stakes or joint venture investments. In May 2025, subsidiary Basel Medical Group Pte. Ltd. executed a tripartite procurement and financing agreement with Pancare Technology International (HK) Limited to source and deliver medical equipment and personal protective products.
In May 2025, management announced a prospective Bitcoin acquisition strategy for corporate treasury management. However, in July 2025, the company officially placed the plan on hold due to regulatory developments surrounding digital assets. Management confirmed that cryptocurrency treasury acquisition plans remain on hold with no intention to resume.
5. Power & Control: Basel Medical Group Ltd Executive Leadership & Ownership
The Brain Trust: Board of Directors & Executive Leadership
The company is governed by a board of directors comprising six members—two executive directors and four independent directors—and supported by experienced senior management in finance and enterprise operations.
Executive Officers & Board Members:
- Dr. Darren Yen Feng Chhoa (Chief Executive Officer): Age 39. Joined the Group in June 2024. Dr. Chhoa leads executive strategy, enterprise business development, clinical service expansion, and healthcare partnerships. He previously served as Medical Director and Vice President at Fullerton Healthcare Group (2016–2022) and Senior Director of Health Services at MHC Health / HMI Group (2022–2024).
- Alton Chun How Neo (Interim Chief Financial Officer): Age 41. Joined the Group in June 2026. Mr. Neo oversees financial strategy, reporting, corporate restructuring, and accounting compliance. He previously served as Deputy CEO of Singapore Operations at InCorp Global and Tax Policy Associate at the Singapore Ministry of Finance. He holds an MBA from the University of Hull, is a Chartered Valuer, and holds CA Singapore and CPA Australia credentials.
- Tan Boon Chye (Darren) (Chief Commercial Officer): Age 46. Joined the Group in August 2025. Mr. Tan directs corporate business development, commercial sales, marketing, and institutional partner arrangements. Co-founder of multiple corporate ventures, he holds a BSc in Accounting & Finance from the University of London.
- Xinwen Yang (Director & Chairman of the Board): Age 51. Appointed to the board in September 2026. Mr. Yang brings extensive operational experience in digital healthcare, senior care, and emergency training, having served as Market Operations President at Qilu Dakang Digital Technology Co., Ltd. and Expert Adviser to Lions Clubs International Health Committee.
- Juan Cao (Director): Age 39. Appointed to the board in September 2026. Ms. Cao possesses over 15 years of experience in business administration, commercial negotiations, and project execution, previously serving as Business Manager at Chengdu Huiya Innovation Education Research Institute. She holds a law degree from Sichuan Normal University.
- Paul Freudenthaler (Independent Director): Age 62. Serves as Audit Committee Chairman. Former CFO and current board member of Freight Technologies Inc. (NASDAQ: FRGT), Mr. Freudenthaler previously held senior CFO positions at Ascentium Capital, EZ Corp (Mexico), Old Mutual, and Macquarie. He holds an MBA from The Wharton School and a Texas CPA license.
- Tony Chen (Independent Director): Age 62. Serves as Compensation Committee Chairman. CEO of Zirauti Global Ventures and former CEO of Microsoft Indonesia (2002–2009), Group Managing Director at Platindo Group, and Country Sales Director at Oracle Indonesia. Holds a computer science degree from UNINUS.
- Kwek Yoon Soong (Independent Director): Age 60. Serves as Nominating & Corporate Governance Committee Chairman. Former Chief Agency Officer at Prudential Insurance Company Singapore (2018–2022) managing a 5,000-agent distribution force, with extensive executive tenure across Zurich Insurance and Allianz Asia Pacific. Holds a law degree from the National University of Singapore.
- Frederick Shieh Ming Hong (Independent Director): Age 51. Appointed in September 2026. Capital markets and real estate professional with over 24 years of client-facing advisory experience in Singapore with Huttons Asia, DTZ Property, Kim Eng Securities, and OCBC Securities.
Who Owns the Stock?
The following table sets forth share ownership details as of October 27, 2026, reflecting 7,582,111 total issued and outstanding ordinary shares (following the June 2026 reverse share split and the October 2026 offering):
| Shareholder & Beneficial Owner | Ordinary Shares Owned | Ownership (%) | Voting Power (%) |
|---|---|---|---|
| Rainforest Capital VCC (Basel Medical Fund, Fan Mingchun, Wei Hua, Baselcorp Capital) | 850,438 | 11.2 | 11.2 |
| Tan Boon Chye (Darren) (Chief Commercial Officer) | 850,438 | 11.2 | 11.2 |
| Dr. Darren Yen Feng Chhoa (Chief Executive Officer) | 0 | 0.0 | 0.0 |
| Alton Chun How Neo (Interim Chief Financial Officer) | 0 | 0.0 | 0.0 |
| All Directors and Executive Officers as a Group | 850,438 | 11.2 | 11.2 |
6. Strategic Outlook: Basel Medical Group Ltd Growth Catalysts & Key Risks
Competitive Advantages & Economic Moats
Basel Medical Group maintains an established market position in Singapore’s private healthcare sector supported by structural competitive advantages:
- Integrated Care Ecosystem: The seamless operational integration between primary care general practice clinics (Bethesda) and sub-specialty centers (orthopedics, trauma, neurosurgery, physiotherapy) allows for internal patient cross-referrals and integrated care pathways.
- Institutional Insurance & Corporate Partnerships: Direct preferred provider agreements with over 20 leading insurance companies and active corporate healthcare contracts with over 300 companies generate recurring patient volumes.
- MediSave & Integrated Shield Plan Accreditation: Accreditation under Singapore’s national medical savings scheme (MediSave) and private Integrated Shield Plans enables eligible patients to fund elective treatments via national healthcare reserves.
- High-Barrier Hospital Credentials: Key medical practitioners hold surgical accreditation across top private hospital systems in Singapore, including Gleneagles, Mount Elizabeth, Mount Elizabeth Novena, Parkway East, Mount Alvernia, and Farrer Park.
What Could Go Wrong? Key Challenges & Business Risks
Investors analyzing Basel Medical Group should evaluate key business, operational, regulatory, and market risks outlined in the filing:
- Dependence on Key Specialists: Clinical revenue is highly dependent on key medical practitioners. The departure of key specialists could adversely impact clinical volume, brand reputation, and operating revenue.
- Dilution Risk from Common Warrants: The October 2026 public offering included 6,000,000 common warrants exercisable at 110% of the offering price. The warrants feature a zero cash exercise price option, which could result in substantial share issuance without additional cash proceeds to the company, causing equity dilution.
- Securities Class Action Litigation: On July 23, 2026, a securities class action complaint was filed in the Supreme Court of the State of New York naming the company and over 30 other public companies as defendants, alleging Securities Act violations regarding IPO registration disclosures. While management and legal counsel deem the claims without merit, litigation could create legal defense expenses and management distraction.
- Financial Reporting Compliance & Delinquencies: In December 2025, the company received a Nasdaq delinquency notice regarding an incomplete FY2025 Form 20-F missing an auditor opinion due to audit evidence timing surrounding the Bethesda acquisition. The company remediated the filing in March 2026 with a Form 20-F/A containing an unqualified audit opinion; however, future reporting delays could expose the listing to risk.
- Regulatory & Fee Benchmark Standards: Clinical operations are governed by the Ministry of Health (MOH), Singapore Medical Council (SMC), and Health Sciences Authority. Revisions to MOH fee benchmarks or ECEG ethical guidelines governing third-party administrator fees could affect pricing structures.
- Real Estate & Lease Renewals: All clinical premises are operated under short-term commercial leases (typically three years or less). Failure to renew leases on acceptable commercial terms or steep rent increases could increase operating costs.
The Next Chapter: Growth & Expansion Initiatives
Basel Medical Group’s strategic blueprint focuses on evolving from a local clinical practice into a multi-specialty regional healthcare provider across Southeast Asia. Management’s primary growth vectors include:
- Primary Care & Specialist Clinic Expansion: Expanding the Bethesda primary care model while adding complementary sub-specialties including ophthalmology, women’s health, and wellness screening.
- Regional Southeast Asian Footprint: Evaluating strategic joint ventures, clinic acquisitions, and medical management partnerships across high-growth medical markets in Southeast Asia.
- Digital Health & Enterprise Referral Pathways: Accelerating direct-to-consumer digital booking platforms, search engine optimization, and corporate employee health management programs to maximize clinic capacity utilization.
- Targeted Healthcare M&A: Utilizing earmarked capital deposits (including S$4.70 million held in custodian accounts) to acquire accretive private clinical practices and diagnostic centers in Singapore.
The Verdict: Strategic Outlook & Conclusion
Basel Medical Group Ltd has established an integrated healthcare platform in Singapore, combining high-margin specialist orthopedic and neurosurgical practices with a growing network of general practice clinics. Following its initial public offering, capital restructuring, and the integration of Bethesda Medical, the Group expanded revenue by 45.2% in FY2026 while narrowing its pre-tax loss.
The company’s long-term execution will depend on integrating newly acquired primary care practices, retaining key medical specialists, maintaining listing compliance, and executing disciplined corporate growth across Southeast Asia.
❓ Frequently Asked Questions: Basel Medical Group Ltd
What was Basel Medical Group Ltd’s revenue and net income in FY 2026?
In FY 2026, Basel Medical Group Ltd reported total revenue of $12.81 M (▲ 13.2% compared to $11.32 M in the prior fiscal year). Gross profit stood at $9.74 M (gross margin of 76.06 %). Operating profit was -$973.67 K and bottom-line net income was -$1.11 M.
Is Basel Medical Group Ltd profitable and generating positive cash flow in FY 2026?
In FY 2026, Basel Medical Group Ltd reported a net loss of -$1.11 M (PAT margin: -8.69 %). On a cash basis, the company generated -$531.96 K in cash flow from operating activities and invested $191.82 K in capital expenditures, resulting in free cash flow of -$723.77 K. Return on Equity (ROE) was -31.77 % and Cash ROE was -15.18 %.
How much debt, assets, and equity does Basel Medical Group Ltd hold?
As of FY 2026, Basel Medical Group Ltd held $13.75 M in total assets, $10.24 M in total liabilities, and $3.51 M in total stockholders’ equity. Total debt stood at $6.69 M (debt-to-equity ratio of 1.91x). Net working capital was $1.75 M with a current ratio of 1.23x.
Who is the CEO and CFO of Basel Medical Group Ltd?
The Chief Executive Officer (CEO) of Basel Medical Group Ltd is Dr. Darren Yen Feng Chhoa. The Chief Financial Officer (CFO) is Alton Chun How Neo.
Where is Basel Medical Group Ltd headquartered and when was it founded?
Basel Medical Group Ltd is headquartered in 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore 258499. The company traces its founding/incorporation to British Virgin Islands. Total disclosed workforce/headcount is 74 full-time employees (as of June 30, 2026). Its official corporate website is https://baselmedical.com/.
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.